RBCC Explores NASA Technology in Stem Cell Search
<0> Rainbow Coral Corp.Patrick Brown, 813-367-9511President and CEO </0>
Rainbow Biosciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), announced today that it is exploring the possible use of micro-gravity technology developed by NASA to produce three-dimensional adult stem cells for medical research purposes.
RBCC announced on Monday that it will expand its focus on technology capable of culturing 3D cell clusters to include adult stem cells. The company is currently investigating the potential for a bioreactor developed for the space program to grow tissues from adult stem cells for possible study and even transplantation. Stem cells grown using the NASA technology multiply rapidly and remain three dimensional, unlike the two-dimensional cells grown in Petri dishes.
This characteristic makes possible the production of healthy populations of cheaper and higher-quality stem cells suitable for all manner of research.
“This technology has the potential to be one of NASA’s greatest gifts to medical sciences,” said RBCC CEO Patrick Brown. “The ability to cultivate adult stem cells in a micro-gravity environment here on earth could prove to be a great leap forward in the field of biotechnology, and we’re very interested in discussing how we might be able to assist in the development and marketing of new therapies and other uses for this device.”
According to a report published last year by analysts as GIA, global investments in adult stem-cell research are forecast to reach $2.4 billion by 2015. RBCC is currently exploring ways to capitalize on that growth. The company plans to develop technology to compete in the stem-cell research industry alongside Amgen, Inc. (NASDAQ: AMGN), Celgene Corporation (NASDAQ: CELG), Genzyme Corp. (NASDAQ: GENZ) and Gilead Sciences Inc. (NASDAQ: GILD).
For more information on Rainbow BioSciences, please visit .
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at . For investment information and performance data on the company, please visit .
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.